Shuimu is a rapidly evolving global cryo-EM & AI platform for early drug discovery, founded in 2017 and headquartered in Beijing, China. Shuimu drives innovation to accelerate the development of innovative drugs. Shuimu leverages the power of cutting-edge cryo-EM & AI technology to help its partners gain key structural insights into the target proteins and complexes. The team consists of top talents with global backgrounds in the field of structural biology, machine learning, protein science, and drug chemistry. Learn more about Shuimu and check out its cryo-EM precision imaging platform by visiting shuimubio.com or sending an email to hi@shuimubio.com.
Company Details
- Employees
- 25
- Founded
- -
- Address
- Zgc Life Science Park, Beijing,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://shuimubio.com/
- Keywords
- Drug discovery, Cryo-EM, MicroED, DrugDevelopment, ProteinStructure, Biophysics, Antibodies, Virology, Nanoparticles, AAV, StructuralBiology, CRO, PPI, Exosomes, Liposomes.
- HQ
- Beijing
Shuimu Biosciences Questions
Shuimu Biosciences's website is http://shuimubio.com/
Shuimu Biosciences's LinkedIn profile is https://www.linkedin.com/company/shuimu
Shuimu Biosciences has
25 employees.
View email and phone details for 25
employees at Shuimu Biosciences.
Shuimu Biosciences's industry is
Biotechnology Research
Shuimu Biosciences's top competitors are
Thundersoft,
Cryocloud,
Protagonist Therapeutics,
Generate:biomedicines,
Bighat Biosciences,
Wuxi Apptec,
Yobo,
北京金匙生物科技有限公司,
Biortus,
Kimia Therapeutics.
Shuimu Biosciences's categories are Biotechnology Research
Shuimu Biosciences's founding year is 2017
